The Challenge of Achieving Target Drug Concentrations in Clinical Trials: Experience From the Symphony Study
Authors:
- Henrik EkbergHEHenrik Ekberg
- Richard D. MamelokRMRichard D. Mamelok
- Thomas C. PearsonTPThomas C. Pearson
- Flavio VincentiFVFlavio Vincenti
- Hélio Tedesco-SilvaHTHélio Tedesco-Silva
- Pierre DalozePDPierre Daloze
- 15 May 2009
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 87 (9) , 1360-1366
Abstract
The Symphony study compared four immunosuppressant regimens, defined by protocol-specified target drug concentrations. This subanalysis examines actual drug levels and the implications on the interpretation of results. De novo renal transplant patients (n=1645) were randomized to receive mycophenolate mofetil (2 g/day) and corticosteroids in combination with standard-dose cyclosporine A (CsA; 150-300 ng/mL for 3 months then 100-200 ng/mL), or daclizumab induction and low-dose CsA (50-100 ng/mL), low-dose tacrolimus (Tac; 3-7 ng/mL), or low-dose sirolimus (SRL; 4-8 ng/mL). Low-dose Tac was significantly superior for renal function, acute rejection, and graft survival at 12 months. Median trough levels of CsA, Tac, or SRL were toward the high end of target ranges in all groups, and 50% to 60% were within target. During weeks 1 to 8, only 6.5% to 11.0% of patients were consistently within target. At week 8, the range of concentrations encompassing 75% of patients on standard-dose CsA was 141 to 321 ng/mL; for low-dose CsA, 62 to 159 ng/mL; for low-dose Tac, 4.3 to 10.0 ng/mL, and for low-dose SRL, 4.4 to 11.2 ng/mL. The protocol-defined target levels were approximately, but not fully achieved. To replicate the Symphony study results in clinical practice, the protocol-defined drug concentration targets should be aimed for, but the concentrations actually achieved may be regarded as acceptable. Future clinical studies should include measures of how well target drug levels were achieved to better guide further attempts to develop new regimens designed to reduce or eliminate calcineurin inhibitors.Keywords
This publication has 10 references indexed in Scilit:
- Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled TrialTransplantation, 2008
- Reduced Exposure to Calcineurin Inhibitors in Renal TransplantationNew England Journal of Medicine, 2007
- Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal TransplantationAmerican Journal of Transplantation, 2007
- Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR StudyAmerican Journal of Transplantation, 2007
- Therapeutic Drug Monitoring of Mycophenolate Mofetil in TransplantationTherapeutic Drug Monitoring, 2006
- Organ Exchanges: Fairness to the O-Blood GroupAmerican Journal of Transplantation, 2006
- Pilot Randomized Study of Early Tacrolimus Withdrawal from a Regimen with Sirolimus Plus Tacrolimus in Kidney TransplantationAmerican Journal of Transplantation, 2004
- Two Doses of Daclizumab in Conjunction with Low‐Dose Cyclosporine, Mycophenolate Mofetil and Steroids Resulted in a Low Incidence of Acute Rejection after Renal TransplantationScandinavian Journal of Immunology, 2003
- A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipientsTransplantation, 2003
- The use of an anti‐CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low‐dose tacrolimus and early withdrawal of steroids in renal transplant recipientsClinical Transplantation, 2003